NET Biology Platform
NETOsys is an innovative Quebec life science company focused on developing advanced screening and diagnostic tools for diseases including cancer, cardiovascular, neurodegenerative, and immunological conditions. NETOsys combines research, technology development, and translational expertise to build blood based NET quantification approaches intended to support disease detection, monitoring, patient stratification, and future therapy-selection research.
Science
Neutrophil extracellular traps (NETs) are web like structures composed of decondensed chromatin decorated with antimicrobial proteins, released by activated neutrophils as part of the innate immune response. Originally described as a host defense mechanism against pathogens, NETs are now recognized as central mediators in a wide range of pathological conditions when dysregulated.
Emerging evidence has positioned NETs at the intersection of inflammation, thrombosis, and tissue damage. Excessive or persistent NET formation contributes to the pathogenesis of autoimmune diseases, cardiovascular disorders, cancer progression, chronic lung diseases, and metabolic syndromes. NETs promote endothelial dysfunction, drive immunothrombosis, and can directly modulate tumor growth and metastasis, highlighting their broad impact across disease areas.
Despite their clinical significance, NETs remain underutilized as diagnostic and therapeutic targets. Advances in biomarker discovery are enabling the quantification of NET associated components such as cell free DNA, histones, and neutrophil derived enzymes, opening new opportunities for early detection, patient stratification, and treatment monitoring.
NETOsys is developing NET biology into diagnostic and translational research tools. By studying molecular mechanisms that govern NET formation and clearance, the company aims to support more precise NET measurement and future strategies for inflammatory, thrombotic, and oncologic disease applications.
Through scientific rigor and translational development, NETOsys is working to convert a fundamental biological process into potential biomarkers and future diagnostic and therapeutic targets.
Pipeline
Current development
The lead assay is being defined across oncology, cardiovascular, and autoimmune cohorts with emphasis on biomarker specificity, sensitivity, and disease relevance.
In parallel, NETOsys is building the assay workflow for sample handling, analytical readout, and interpretation of NET-associated signatures, with the goal of supporting research and future clinical laboratory settings.
Planned next-phase work extends the lead assay into inflammatory and thrombo-inflammatory settings where NET biology may help stratify disease state or treatment response.
A later regulatory path would focus on analytical validation, clinical performance studies, and relevant diagnostic or companion diagnostic framework considerations.
As the same platform matures, one development path can support several downstream formats rather than separate active products.
Company